Bellicum Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference

HOUSTON--(BUSINESS WIRE)-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Tom Farrell, President and CEO, will present at the Ladenburg Thalmann 2016 Healthcare Conference. The presentation will take place on Tuesday, September 27, 2016 at 10:00 a.m. EDT in New York City.

A live webcast of the presentation may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160920005082/en/

Bellicum Pharmaceuticals
Investors:
Alan Musso, 832-384-1116
CFO
[email protected]
or
Media:
BMC Communications
Brad Miles, 646-513-3125
[email protected]

Source: Bellicum Pharmaceuticals, Inc.

You May Also Be Interested In

• BingX Card Now Available to All Eligible Users, Bringing Crypto Rewards to Everyday Spending
• GoldHaven Confirms Favourable Critical Minerals Geological Settings Across 123,900-Hectare Brazil Portfolio
• Peraso to Showcase 60 GHz mmWave Technology for Advanced Drone Communications at 11th Annual UAV Technology Conference